ANTI-CD40 ANTIBODY-BINDING MODULATES HUMAN MULTIPLE-MYELOMA CLONOGENICITY IN-VITRO

被引：0
|
作者：
TONG, AW
SU, D
MUES, G
SOLANO, M
STONE, MJ
机构：
[1] BAYLOR UNIV,BAYLOR SAMMONS CANC CTR,MED CTR,DALLAS,TX
[2] BAYLOR RES INST,M CROWLEY LAB,DALLAS,TX
来源：
BLOOD | 1994年 / 84卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A170 / A170
页数：1
相关论文
共 50 条
  • [31] The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells
    Luqman, Mohammad
    Klabunde, Sha
    Lin, Karen
    Georgakis, Georgios V.
    Cherukuri, Anu
    Holash, Jocelyn
    Goldbeck, Cheryl
    Xu, Xiaomei
    Kadel, Edward E., III
    Lee, Sang Hoon
    Aukerman, Sharon Lea
    Jallal, Bahija
    Aziz, Natasha
    Weng, Wen-Kai
    Wierda, William
    O'Brien, Susan
    Younes, Anas
    BLOOD, 2008, 112 (03) : 711 - 720
  • [32] ENHANCEMENT OF ANTI-CD54 IMMUNOTOXIN CYTOTOXICITY TO HUMAN MULTIPLE-MYELOMA CELLS BY CYCLOSPORINE DRUGS
    TONG, AW
    HUANG, YW
    GHETIE, V
    NEMUNAITIS, J
    PINEIRO, L
    VITETTA, E
    STONE, MJ
    BLOOD, 1994, 84 (10) : A170 - A170
  • [33] Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates
    Kelley, Sean K.
    Gelzleichter, Thomas
    Xie, Dong
    Lee, Wyne P.
    Darbonne, Walter C.
    Qureshi, Ferhan
    Kissler, Kim
    Oflazoglu, Ezogelin
    Grewal, Iqbal S.
    BRITISH JOURNAL OF PHARMACOLOGY, 2006, 148 (08) : 1116 - 1123
  • [34] The novel anti-CD40 monoclonal antibody CFZ533 modulates biomarkers relevant to disease and CD40 pathways in patients with primary Sjogren's syndrome
    Fisher, Benjamin
    Zeher, Margit
    Ng, Wan-Fai
    Bombardieri, Michele
    Posch, Maximilian
    Papas, Athena S.
    Farag, Arwa M.
    Daikeler, Thomas
    Bannert, Bettina
    Kivitz, Alan J.
    Carsons, Steven E.
    Isenberg, David A.
    Barone, Francesca
    Bowman, Simon
    Espie, Pascal
    Wieczorek, Grazyna
    Moulin, Pierre
    Floch, David
    Dupuy, Cyrielle
    Ren, Xiaohui
    Faerber, Petra
    Wright, Andrew M.
    Hockey, Hans Ulrich
    Rotte, Michael
    Healey, Margaret
    Kazma, Remi
    Sarrazin, Anita Auger
    Kaiser, Stephanie
    Mueller, Eric Chen Annemarie
    Wache-Mainier, Clarisse
    Macchiarella, Giulio
    Avrameas, Alexandre
    Sommer, Ulrike
    Valentin, Marie-Anne
    Doucet, Julie
    Sultan, Marc
    Schlitt, Thomas
    Gergely, Peter
    Rush, James S.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2018, 36 (03) : S245 - S246
  • [35] The humanized anti-CD40 monoclonal antibody SGN-40 targets Hodgkin's disease cells through multiple mechanisms.
    Law, CL
    McEarchern, JA
    Cerveny, CG
    Smith, LM
    Nesterova, A
    Gordon, KA
    Grewal, IS
    Wahl, AF
    BLOOD, 2005, 106 (11) : 425A - 426A
  • [36] Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies
    Horton, Holly M.
    Bernett, Matthew J.
    Peipp, Matthias
    Pong, Erik
    Karki, Sher
    Chu, Seung Y.
    Richards, John O.
    Chen, Hsing
    Repp, Roland
    Desjarlais, John R.
    Zhukovsky, Eugene A.
    BLOOD, 2010, 116 (16) : 3004 - 3012
  • [37] Development, validation and application of ELISAs for pharmacokinetic and HACA assessment of a chimeric anti-CD40 monoclonal antibody in human serum
    Chowdhury, F.
    Tutt, A. L.
    Chan, C.
    Glennie, M.
    Johnson, P. W.
    JOURNAL OF IMMUNOLOGICAL METHODS, 2010, 363 (01) : 1 - 8
  • [38] Characterization of the in vitro and in vivo properties of CFZ533, a blocking and non-depleting anti-CD40 monoclonal antibody
    Ristov, Jacinda
    Espie, Pascal
    Ulrich, Peter
    Sickert, Denise
    Flandre, Thierry
    Dimitrova, Mirela
    Mueller-Ristig, Dorothee
    Weider, Doris
    Robert, Gautier
    Schmutz, Patrick
    Greutmann, Barbara
    Cordoba-Castro, Francisco
    Schneider, Martin A.
    Warncke, Max
    Kolbinger, Frank
    Cote, Serge
    Heusser, Christoph
    Bruns, Christian
    Rush, James S.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 (12) : 2895 - 2904
  • [39] A phase I dose escalation study of a fully human, antagonist Anti-CD40 antibody, HCD122 (formerly CHIR-12.12) in patients with relapsed and refractory multiple myeloma.
    Bensinger, William
    Jagannath, Sundar
    Becker, Pamela S.
    Anderson, Kenneth C.
    Stadtmauer, Edward A.
    Aukerman, Lea
    Fox, Judith
    Girish, Sandhva
    Bilic, Sanela
    Guzy, Serge
    Solinger, Alan
    Dort, Sherri
    Wang, Yongyu
    Hurst, Deborah
    BLOOD, 2006, 108 (11) : 1021A - 1021A
  • [40] CD40 Expression by Human Melanocytic Lesions and Melanoma Cell Lines and Direct CD40 Targeting With the Therapeutic Anti-CD40 Antibody CP-870,893
    Kalbasi, Anusha
    Fonsatti, Ester
    Natali, Pier Giorgio
    Altomonte, Maresa
    Bertocci, Erica
    Cutaia, Ornella
    Calabro, Luana
    Chiou, Michael
    Tap, William
    Chmielowski, Bartosz
    Maio, Michele
    Ribas, Antoni
    JOURNAL OF IMMUNOTHERAPY, 2010, 33 (08) : 810 - 816
12345